You are here

Generic Wellbutrin SR Now Available

CORONA, Calif., March 22 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that, under a supply agreement with GlaxoSmithKline (GSK), Watson has initiated shipments of bupropion hydrochloride sustained-release tablets, in the 150mg strength. The product is the generic version of GlaxoSmithKline's Wellbutrin SR®, which is indicated for the treatment of depression. For the 12-months ending January 2004, Wellbutrin SR® 150mg had sales of approximately $1.2 billion, according to IMS Health data.

Under a previously announced settlement with GSK, Watson received rights in the United States (US) market to distribute 100mg and 150mg bupropion hydrochloride sustained-release tablets, manufactured by a GSK subsidiary, on a per strength basis, once a third party launches a fully substitutable generic equivalent of the relevant strength of these products in the US market. Watson launched bupropion hydrochloride sustained-release tablets in the 100mg strength in January 2004. GSK will receive a share of the profits from Watson's sales of generic bupropion hydrochloride sustained-release tablets in the US market. Terms of the agreement were not disclosed.

Source: Watson Pharmaceuticals, Inc.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
National Statistics Report Factors In Race, Ethnicity for the First Time